ArticleTranslational oncology2008
Molecular characterization of synovial sarcoma in children and adolescents: evidence of akt activation.
Article in Translational oncology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 39 citations in OpenAlex.
- Revealing novel subtypes of synovial sarcoma through single cell transcriptomics.NPJ systems biology and applications · 2026Article
- A case of primary tarsal sinus synovial sarcoma.Diagnostic pathology · 2025Article
- Article
- Primary Intraosseous Synovial Sarcoma in the Mandible.Case reports in oncological medicine · 2021Article
- Synovial Sarcoma: A Complex Disease with Multifaceted Signaling and Epigenetic Landscapes.Current oncology reports · 2020Review
- TP53 in bone and soft tissue sarcomas.Pharmacology & therapeutics · 2019Review
- The PTEN Tumor Suppressor Gene in Soft Tissue Sarcoma.Cancers · 2019Review
- Article
- Establishment and proteomic characterization of a novel synovial sarcoma cell line, NCC-SS2-C1.In vitro cellular & developmental biology. Animal · 2018Article
- Therapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcoma.BMC cancer · 2017Article
- Down-Regulation of AKT Signalling by Ursolic Acid Induces Intrinsic Apoptosis and Sensitization to Doxorubicin in Soft Tissue Sarcoma.PloS one · 2016Article
- Synovial sarcoma: recent discoveries as a roadmap to new avenues for therapy.Cancer discovery · 2015Review
- A phase I trial of MK-2206 in children with refractory malignancies: a Children's Oncology Group study.Pediatric blood & cancer · 2014Article
- Pediatric sarcomas: translating molecular pathogenesis of disease to novel therapeutic possibilities.Pediatric research · 2012Review
- A challenging case of metastatic intra-abdominal synovial sarcoma with unusual immunophenotype and its differential diagnosis.Case reports in pathology · 2012Article
- Article
- Correlation between DNA ploidy, metaphase high-resolution comparative genomic hybridization results and clinical outcome of synovial sarcoma.Diagnostic pathology · 2011Article
- EGR1 reactivation by histone deacetylase inhibitors promotes synovial sarcoma cell death through the PTEN tumor suppressor.Oncogene · 2010Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Synovial sarcoma (SS) is the most frequent nonrhabdomyosarcomatous soft tissue sarcoma encountered in adolescents and young adults, and despite advances in the treatment of local disease, metastases remain the main cause of death. The aim of this study was to characterize a single-center series of pediatric SS molecularly to seek any biomarkers or pathways that might make suitable targets for new agents. Seventeen cases of pediatric SS showing the SYT-SSX fusion transcript were screened immunohistochemically, biochemically, molecularly, and cytogenetically (depending on the available material) to investigate any expression/activation of epidermal growth factor receptor, platelet-derived growth factor receptor alpha (PDGFRalpha), PDGFRbeta, Akt, and deregulated Wnt pathway. The most relevant outcome was the finding of activated epidermal growth factor receptor, PDGFRalpha, and PDGFRbeta, which activated Akt in both the monophasic and biphasic histologic subtypes. Consistently, Akt activation was completely abolished in an SS cell line assay when stimulated by PDGF-AA and treated with the phosphatidylinositol 3-kinase inhibitor LY294002. Our results also showed the nuclear localization of beta-catenin and cyclin D1 gene products in monophasic SS and the movement of beta-catenin into the cytoplasm in the glandular component of the biphasic subtype. Although they need to be confirmed in larger series, these preliminary data suggest that therapeutic strategies including specific inhibitors of the phosphatidylinositol 3-kinase/Akt pathway might be exploited in SS.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.